Drug Trial Radar · NCT04197934
WSD0922-FU for Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases
Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
56
Actual
Start
Dec 20, 2019
Primary completion
Oct 30, 2022
Study completion Feb 6, 2031
Sponsor
- Lead sponsor
- Mayo ClinicAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 13, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I trial studies the side effects and best dose of WSD0922-FU for the treatment of glioblastoma, anaplastic astrocytoma, or non-small cell lung cancer that has spread to the central nervous system (central nervous system metastases). WSD0922-FU is a targeted treatment which blocks the EGFR protein - a strategy that has led to a lot of benefit in patients with many different cancers. WSD0922-FU may also be able to get into cancers in the brain and spinal cord and help patients with brain and spinal cord cancers. Funding Source - FDA OOPD
Conditions
- Anaplastic Astrocytoma, IDH-Wildtype
- Glioblastoma, IDH-Wildtype
- Metastatic Lung Non-Small Cell Carcinoma
- Metastatic Malignant Neoplasm in the Central Nervous System
- Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection - blood samplesProcedure
Undergo collection of blood samples
Biospecimen Collection - CSF samplesProcedure
Undergo collection of CSF samples
Computed TomographyProcedure
Undergo CT
EGFR/EGFRvIII Inhibitor WSD0922-FUDrug
Given PO
Magnetic Resonance ImagingProcedure
Undergo MRI
Therapeutic Conventional SurgeryProcedure
Undergo surgical resection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recommended phase 2 doseTime frame: Up to 28 days
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic in Arizona
Scottsdale, Arizona
Mayo Clinic in Florida
Jacksonville, Florida
Mayo Clinic in Rochester
Rochester, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.